CClinicalTrials.gg
CompletedNCT03172481Updated Nov 5, 2019Results posted

PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD

A Phase 3 interventional study of PRC-063 oral capsules and Placebo oral capsules in ADHD, sponsored by Purdue Pharma, Canada. Completed at 6 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-11-05.

Sponsored by Purdue Pharma, Canada · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.

02

Conditions studied

  • ADHD
03

In context

Lead sponsor

Purdue Pharma, Canada is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Males or females greater than or equal to 6 and less than or equal to 12 years of age
  2. Females who are non-pregnant and non-nursing
  3. Females of child-bearing potential who agree to practice a clinically accepted method of contraception during the study and for at least one month prior to study dosing and one month following completion of the study. Acceptable contraceptive methods include abstinence, oral contraception, surgical sterilization (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), intrauterine device, or diaphragm in addition to spermicidal foam and condom on male partner, or systemic contraception (e.g. levonorgestrel-releasing implant)
  4. Diagnosis of ADHD (any type: combined, predominately hyperactive impulsive type or predominately inattentive type) by a psychiatrist, psychologist, developmental pediatrician or licensed allied healthcare professional using the DSM-5 and confirmed by administration of a structured diagnostic interview using the K-SADS-PL
  5. Ratings on the ADHD-RS-5 based on when the subject is not receiving treatment for ADHD, the subject must have ≥ 90th percentile normative value for gender and age in at least 1 of the categories: total score, inattentive subscale or hyperactive/impulse subscale
  6. Unsatisfied with his or her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD. Inclusion of subjects who are naïve to pharmacological therapy for ADHD is permitted
  7. Must be functioning at an age-appropriate level intellectually as determined by an intelligence quotient of ≥ 80 on a documented IQ assessment such as the WASI-II vocabulary and matrix reasoning components, or the KBIT-2
  8. Must have the ability to complete the PERMP assessments
  9. Have parental consent (signed informed consent form) and written or verbal assent from the subject
  10. Subject and parent(s)/caregiver are willing and able to comply with all the protocol requirements and parent(s) or caregiver must be able to provide transportation for the subject to and from the analog classroom sessions

Exclusion criteria

Exclusion Criteria:

  1. Has blood pressure and pulse greater than the 95th percentile for age and gender
  2. Has current or recent history (within the past 6 months) of drug abuse or dependence disorder in the subject or the immediate family or by someone living at the participant's' home or positive urine drug screen for stimulant medication (other than currently prescribed stimulant for the treatment of ADHD) or drugs of abuse at the screening visit
  3. Has untreated thyroid disease, glaucoma, Gilles de la Tourette's disorder, chronic tics or a history of seizures during the last 2 years (except simple febrile seizures), a tic disorder (exclusive of transient tic disorder). Mild medication-induced tics are not exclusionary
  4. Primary and/or comorbid psychiatric diagnosis other than ADHD with the exception of simple phobias, motor skill disorders, communication disorders, learning disorders and adjustment disorders so long as such disorder is judged not to interfere with study participation or the safety of the subject or other participants. Children meeting conduct disorder or oppositional defiant disorder criteria but without history of prominent aggressive outbursts that could interfere with study participation or the safety of the subject or other participants will be allowed to enroll at the discretion of the investigator
  5. Subjects with a family history (first degree relatives) of sudden cardiac death require review and approval by the medical monitor for participation in the study
  6. Has a current or recent history of hypertension, symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug
  7. Has a concurrent medical condition that, in the opinion of the investigator, could cause participation in this study to be detrimental to the subject
  8. Has used any investigational drug within 30 days of the screening visit
  9. Has a known history of physical, sexual, or emotional abuse in the last year
  10. Has a medical history of hepatitis A, B, C or human immunodeficiency virus, or tests positive for any of these at screening
  11. Has a positive urine pregnancy test (if applicable) at screening
  12. Has positive findings on C-SSRS for suicidal ideation or behaviors at screening.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Active Treatment

    PRC-063 25, 35, 45, 55, 70 or 85 mg

    Drug: PRC-063 oral capsules

  • Placebo comparator
    Placebo Treatment

    Drug: Placebo oral capsules

Interventions

  • DrugPRC-063 oral capsules

    Daily dose

  • DrugPlacebo oral capsules

    Daily dose

06

What researchers measure

Primary outcomes

  1. Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom

    The SKAMP rating scale is a validated tool that assesses behavioral symptoms of ADHD in a classroom setting. The SKAMP-C comprises 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13), and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0 = none, 6 = maximal impairment), for a total possible combined score of 0 to 78 (lower score indicated fewer ADHD symptoms). During the Full-day Classroom visit, SKAMP-C was assessed at pre-dose and approximately 1, 2, 4, 6, 8, 10, 12, and 13 hours post-dose. Average post-dose score and change from pre-dose score were analyzed on the individual SKAMP-C scores.

    Time frame: Full-day Classroom - 13 hrs

07

Results

Posted Jun 4, 2019

Participant flow

Open-label
Participant flow — Open-label
MilestonePRC-063Placebo
Started1560
Completed1480
Not completed80
Double-blind
Participant flow — Double-blind
MilestonePRC-063Placebo
Started7573
Completed7473
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimarySwanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom

The SKAMP rating scale is a validated tool that assesses behavioral symptoms of ADHD in a classroom setting. The SKAMP-C comprises 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13), and is obtained by summing up each item score where each item is rated on a 7-point impairment scale (0 = none, 6 = maximal impairment), for a total possible combined score of 0 to 78 (lower score indicated fewer ADHD symptoms). During the Full-day Classroom visit, SKAMP-C was assessed at pre-dose and approximately 1, 2, 4, 6, 8, 10, 12, and 13 hours post-dose. Average post-dose score and change from pre-dose score were analyzed on the individual SKAMP-C scores.

Time frame:
Full-day Classroom - 13 hrs
Reported as:
Mean · score on SKAMP-C
Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom
score on SKAMP-CPRC-063Placebo
Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom11.4 ± 6.918.2 ± 9.0
Statistical analysis
  • PRC-063 vs Placebo · ANOVA · p = <0.0001

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRC-0630/74 (0%)0/74 (0%)10/74 (13.5%)
Placebo0/73 (0%)0/73 (0%)3/73 (4.1%)
Most frequent other events
Most frequent other events
EventPRC-063Placebo
Heart Rate IncreasedInvestigations3/741/73
Sinus TachycardiaCardiac disorders1/742/73
VomitingGastrointestinal disorders2/740/73
HeadacheNervous system disorders2/740/73
Upper Respiratory Tract InfectionInfections and infestations2/740/73

Baseline characteristics

Age, Customized
Age, Customized(years)PRC-063PlaceboTotal
Age9.4 ± 1.899.4 ± 1.839.4 ± 1.85
Sex: Female, Male
Sex: Female, Male(Participants)PRC-063PlaceboTotal
Female272451
Male474996
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PRC-063PlaceboTotal
Hispanic or Latino212142
Not Hispanic or Latino5352105
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRC-063PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American253358
White473481
More than one race257
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PRC-063PlaceboTotal
United States7473156
08

Study locations

6 sites
  • AVIDA Inc.
    Newport Beach, California 92660, United States
  • Meridien Research Inc.
    Bradenton, Florida 34201, United States
  • Meridien Research Inc.
    Maitland, Florida 32751, United States
  • Qps Mra Llc
    Miami, Florida 33143, United States
  • Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada 89128, United States
  • Bayou City Research
    Houston, Texas 77007, United States
09

References and documents

Publications

  • Childress AC, Brams MN, Cutler AJ, Donnelly GAE, Bhaskar S. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2020 Dec;30(10):580-589. doi: 10.1089/cap.2020.0109. Epub 2020 Oct 22. PubMed 33090921 ↗

Study documents

  • Protocol and statistical analysis plan · Jul 11, 2017

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03172481
Lead sponsor
Purdue Pharma, Canada
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
May 1, 2017
Primary completion
Aug 19, 2017
Completion
Dec 19, 2017
Results posted
Jun 4, 2019
Last update
Nov 5, 2019

Study contacts

Sailaja Bhaskar, PhD
study director · Purdue Pharma, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion